Table 1. Associations of clinicopathological features with MTAP immunoexpression and gene status in primary myxofibrosarcomas.

MTAP Expression (n=87)			p-value	MTAP Gene (n=79)		p-value
	Deficient	Positive		HD	Non-HD
Sex			1.000			0.936
Male	18	31		8	23
Female	14	24		12	36
Age			1.000			0.854
<60 years	12	21		23	7
≥60 years	20	30		37	13
Location			0.799			0.908
Extremity	23	42		15	45
Axial	9	13		5	14
Tumor necrosis			0.483			0.115
<10%	19	38		41	10
>=10%	13	17		18	10
FNCLCC grade			0.534			0.006*
grade 1	13	25		30	4
grade 2	12	23		24	9
grade 3	7	7		5	7
AJCC stage			0.763			0.097
Stage 1	6	14		16	1
Stage 2	12	19		21	9
Stage 3	13	20		20	10
Tumor size&	7.314±6.528	6.347±3.701	0.633	6.600 4.808	7.311 5.551	0.612
Mitotic rate&	12.81±13.143	10.33±1.695	0.585	8.780±9.180	19.050±15.408	0.011*
MTAP gene status			<0.001
Aberration (HD, PM)	26 (16,10)	4 (4,0)
No aberration (no HD or PM detected)	3	46

HD: homozygous deletion, PM: promoter methylation,

^*:Statistically significant,

^&:t-test,